Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Sumitomo Pharma America, Inc.
Primary Objective: • To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of oral TP-3654 in patients with advanced solid tumors. Secondary Objectives: * To establish the pharmacokinetic (PK) profile of orally administered TP-3654 * To observe patients for any evidence of antitumor activity of TP-3654 by objective radiographic assessment * To study the pharmacodynamic effects of TP-3654 therapy * To establish the Recommended Phase 2 Dose (RP2D) for future studies with TP-3654
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted